SPN-817 for Epilepsy

This trial tests a new treatment called SPN-817 to determine its safety and tolerability for adults with epilepsy unresponsive to standard treatments. It targets individuals who have tried at least two other seizure medications without success and continue to experience seizures. Eligible participants should be able to track their seizures and have had at least four seizures in a recent six-week period. The goal is to find better options for managing difficult-to-treat seizures. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to potential advancements in epilepsy care.

The trial requires that you continue taking at least one anti-seizure medication (ASM) during the study. However, you cannot change your ASM regimen during the Screening, Titration/Optimization, or Maintenance Periods. Changes are only allowed during the Open-Label Extension (OLE) Period.

Research has shown that SPN-817, a treatment under study for epilepsy, has undergone safety testing in several studies. Participants in these studies experienced some common side effects, which were generally manageable. One study found that doses between 3 mg and 4 mg significantly reduced seizure frequency, indicating good tolerance at these levels. While some side effects were reported, they were typical for epilepsy treatments. SPN-817 remains in the middle phase of testing, suggesting a moderate level of safety evidence. Ongoing research aims to fully understand its safety profile.¹²³⁴⁵

Unlike the standard treatments for epilepsy, which often include drugs like valproate, carbamazepine, or lamotrigine, SPN-817 is derived from a different class of compounds that may offer a novel mechanism of action. Researchers are particularly excited about SPN-817 because it is being tested as a twice-daily oral treatment, which could simplify dosing schedules and improve patient compliance. Additionally, this treatment might provide a new avenue for patients who have not responded well to existing medications, potentially reducing seizure frequency with fewer side effects.

Research has shown that SPN-817, the investigational treatment in this trial, may help reduce seizures in people with hard-to-treat epilepsy. One study reported a 54.5% drop in seizures over 28 days among participants. Another study found an average seizure reduction of 58%. Long-term results suggest that SPN-817 can lead to a 71% decrease in seizures after 15 months. These findings indicate that SPN-817 could effectively lower seizure frequency.¹²³⁴⁶